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ARTICLE
The Genome of the Netherlands: design, and
project goals
Dorret I Boomsma*,1,22, Cisca Wijmenga2,22, Eline P Slagboom3,22, Morris A Swertz2,22, Lennart C Karssen4,
Abdel Abdellaoui1, Kai Ye3, Victor Guryev5,6, Martijn Vermaat7,8,9, Freerk van Dijk2, Laurent C Francioli10,
Jouke Jan Hottenga1, Jeroen FJ Laros7,8,9, Qibin Li11, Yingrui Li11, Hongzhi Cao11, Ruoyan Chen11, Yuanping Du11,
Ning Li12, Sujie Cao12, Jessica van Setten10, Androniki Menelaou10, Sara L Pulit10, Jayne Y Hehir-Kwa15,
Marian Beekman16, Clara C Elbers10, Heorhiy Byelas2, Anton JM de Craen16, Patrick Deelen2, Martijn Dijkstra2,
Johan T den Dunnen8,9, Peter de Knijff8,9, Jeanine Houwing-Duistermaat17, Vyacheslav Koval18, Karol Estrada18,
Albert Hofman4, Alexandros Kanterakis2, David van Enckevort7, Hailiang Mai7, Mathijs Kattenberg1,
Elisabeth M van Leeuwen4, Pieter BT Neerincx2, Ben Oostra19, Fernanodo Rivadeneira18, Eka HD Suchiman3,
Andre G Uitterlinden18, Gonneke Willemsen1, Bruce H Wolffenbuttel20, Jun Wang11,13,14,22, Paul IW de Bakker10,22,
Gert-Jan van Ommen21,22 and Cornelia M van Duijn*,4,22
Within the Netherlands a national network of biobanks has been established (Biobanking and Biomolecular Research
Infrastructure-Netherlands (BBMRI-NL)) as a national node of the European BBMRI. One of the aims of BBMRI-NL is to enrich
biobanks with different types of molecular and phenotype data. Here, we describe the Genome of the Netherlands (GoNL), one
of the projects within BBMRI-NL. GoNL is a whole-genome-sequencing project in a representative sample consisting of 250
trio-families from all provinces in the Netherlands, which aims to characterize DNA sequence variation in the Dutch population.
The parent–offspring trios include adult individuals ranging in age from 19 to 87 years (mean¼53 years; SD¼16 years) from
birth cohorts 1910–1994. Sequencing was done on blood-derived DNA from uncultured cells and accomplished coverage was
14–15x. The family-based design represents a unique resource to assess the frequency of regional variants, accurately
reconstruct haplotypes by family-based phasing, characterize short indels and complex structural variants, and establish the
rate of de novo mutational events. GoNL will also serve as a reference panel for imputation in the available genome-wide
association studies in Dutch and other cohorts to refine association signals and uncover population-specific variants. GoNL
will create a catalog of human genetic variation in this sample that is uniquely characterized with respect to micro-geographic
location and a wide range of phenotypes. The resource will be made available to the research and medical community
to guide the interpretation of sequencing projects. The present paper summarizes the global characteristics of the project.
European Journal of Human Genetics (2014) 22, 221–227; doi:10.1038/ejhg.2013.118; published online 29 May 2013
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INTRODUCTION
The last decade has seen rapid developments and breakthroughs in
unraveling the genetic etiology of complex genetic disorders.1
Genome-wide association studies (GWAS) have uncovered
thousands of variants influencing major diseases and complex
human traits, including cardiovascular disease, diabetes, dementia,
schizophrenia, height, and body mass index (BMI). Despite major
successes in gene discovery, for many traits the percentage of variance
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explained by GWAS loci is relatively low, leaving a substantial
part of the variation to be explained. Approaches that estimate
genetic variance based on a large series of GWAS variants such as
GCTA2,3 show that aggregate effects of genome-wide significant
common variants and those that do not reach this criterion explain
substantially larger amounts of variance for, for example, human
height,4 major depression5 or type 1 and 2 diabetes.6 Clearly, GWAS
have not yet reached their limits, as is demonstrated by the many new
loci detected after increasing sample sizes.
The use of dedicated arrays such as the metaboChip and
immunoChip, which include new common and rare variants from
the established GWAS regions, confirm the findings of modeling
studies that the heritability not yet explained is to be found in a
mixture of unmapped and untagged common, and not yet discovered
rare variants.7–10 Despite progress, our knowledge of the regions
identified by GWAS is still limited. Considering that even for ‘simple’
genetic diseases such as cystic fibrosis thousands of relevant mutations
have occurred in a single gene, there is a need for in-depth sequencing
and characterization of the genomic regions identified thus far. In a
selected, relatively small, group of 256 Sardinians with extreme LDL-C
values who were resequenced and reimputed to the 1000 Genomes
Project reference at six GWAS loci, the variance explained for blood
lipid levels at known loci doubled through the identification of both
rare and common variants.11
Thus, identifying low frequency and rare variants by resequencing
will contribute to resolving the missing heritability. As rarer variants
are more likely to be population specific,12 sequencing across a range
of different populations is mandatory for translation into public
health and clinical benefits. One aim of the 1000 Genomes Project is to
create maps of genetic variation across multiple populations, but the
number of individuals per population is modest. Tennessen et al12
identified4500 000 single-nucleotide variants (SNVs) in a sequencing
project of 15 585 human protein-coding genes. The major part of these
SNVs were rare (86% with a minor allele frequencyo0.5%), unknown
(82%) and population-specific (82%). A deep-sequencing study13 of
202 putative drug targets confirmed that most genetic variants occur at
very low frequencies. To characterize a population, it is crucial to
sequence as many individuals as possible to maximize the probability
of capturing rare variants.
Findings from sequencing studies are also important for clinical
applications and public health genetics. The interpretation of the
‘potential causality’ of a novel variant after it has been identified in
patients in a clinical setting, requires knowledge of its frequency in the
population the patient belonged to. In view of its potential research
and clinical applications, the Genome of the Netherlands (GoNL;
http://www.nlgenome.nl) project was initiated as a part of BBMRI-
NL14 (Biobanking and Biomolecular Research Infrastructure-
Netherlands). The aim of GoNL was to sequence 1000 independent
genomes from the Dutch population. These 1000 Genomes come
from a representative sample of 250 parent-pairs with 1 or 2 offspring.
Sequencing was done using genomic DNA to an intended average
depth of 12x for each sample. Here, we describe the design of GoNL
within the demographic setting of the Netherlands, the sampling
frame and basic characteristics of the participants.
Geographically, the Netherlands is a small country of about
41 500 km2. Yet, the Dutch population of nearly 17 million inhabi-
tants constitutes a middle-sized population within Europe and
represents 0.24 percent of the world’s total population. The Nether-
lands were populated by different groups.15,16 Regional isolation and
religious endogamy, as well as rapid population growth had key roles
in shaping the population genetics of the Dutch. Population growth
was low until the 19th century, and doubled between 1900 and 1950
from 5.1 to 10 million people and between 1951 and 2000 to 15.9
million. In 1901, the total fertility rate was 4.53, in 1950 it was 3.10
and in 2000 it had decreased to 1.72. From the 1970s onwards (http://
statline.cbs.nl/StatWeb/publication), the number of non-western
immigrants increased from B1.2% of the population to 10.4% in
2005 and is now stable at 11.6%. Immigrants have been of various
genetic backgrounds, with Turkish and Moroccan origin being the
largest groups followed by those of Asian and African origin from
(former) Dutch overseas areas (Netherlands Antilles, Suriname and
Indonesia). At the design stage of the GoNL project, we decided to
include participants whose ancestors are born in the Netherlands.
Sequencing of other groups was not possible without compromising
the power for all the groups. However, extending sequencing beyond
Caucasians remains a desirable aim.
Another key decision concerned the selection of subjects over
geographic regions. The Netherlands are historically divided into
provinces, which are geographical units with their own governance
dating back from the period that the Netherlands were a republic
(1588–1795). Geographically, the distribution of the population in the
Netherlands is heavily skewed with the majority (75%) of the
population living in the Western and Middle provinces of the country
including North-Holland (16% of the population including the
capital Amsterdam), South-Holland (22% including the largest
European harbor, Rotterdam), North-Brabant (15%, bordering
Belgium, formerly part of the Dutch kingdom), Gelderland
(12%, bordering Germany) and Utrecht (10%; see Table 1 and
Figure 1); only a small fraction lives in the Northern and Southern
provinces. There is considerable evidence for regional differences in
genetic make-up, for example, there is a significant North–South
gradient both in height and eye color.15 Also studies of the
Y-chromosome clearly pinpoint differences in genetic origin.
Representative sampling from the provinces of the Netherlands
according to sample size would lead to major differences in numbers
of subjects sequenced per region. Although this reflects the size and
distribution of the population, many population genetic analyses are
influenced by sample size, including linkage disequilibrium and
founder effects. We, therefore, chose to include an approximately
Table 1 Participants by province of Netherlands, and % of the
population in that region
Province
Size of population
relative to total
(% to total of 15–65
years)
Number of
subjects
included
in GoNL
% of the
GoNL
sample
Number of
twin pairs
Drenthe 2.8 56 7.3
Friesland 3.8 62 8.1
Gelderland 11.9 57 7.4 4 MZ, 2 DZ
Groningen 3.5 57 7.4
Limburg 6.7 58 7.5 1 MZ, 2 DZ
North-Brabant 14.8 68 8.8 1 MZ
North-Holland 16.5 91 11.8 1 MZ
Overijssel 6.7 58 7.5 2 MZ, 2 DZ
Utrecht 9.5 48 6.2 2 MZ
Zeeland 2.2 46 6.0 2 DZ
South-
Holland
21.5 168 21.8
Total 769 19 Twin pairs
Abbreviations: MZ monozygotic, DZ dizygotic.
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equal representation from the original 11 Dutch provinces (see
Table 1), oversampling the two major cities Amsterdam and Rotterdam.
The 12th province, which was established in 1986, was not included, as
it was populated by recent immigration from surrounding areas.
Trio design
A key characteristic of GoNL is its trio design. The sample unit
consists of two parents and one offspring yielding information on
four genomes (two per parent). There were three considerations that
led to the choice of the trio design for GoNL despite the fact that a
trio design reduces the effective sample size by one-third compared
with a design that includes only unrelated individuals. First, a major
aim is to provide a facility for imputation, rapid and valid haplotyp-
ing, and the trio design allowed GoNL to reduce the computational
burden of haplotyping. Second, a trio design would enable reducing
the number of false-positive variant calls by screening for violation of
Mendelian segregation in the trio-aware calling of genotypes. Third,
the trio design would allow for a characterization of new mutations
within the Dutch population, in that novel variants that occur in
offspring but not in parents can be assessed. This latter approach
requires a separate calling and storage of variants in which
non-Mendelian transmission is allowed. Our sequencing at inter-
mediate coverage was considered to be optimal to address these aims.
Selection of samples
In the Netherlands, several large-scale collaborative Biobank consortia
have been established, that bring together patient samples and
population-based collections of biological samples. GoNL is part of
the Dutch branch of BBMRI (http://www.bbmri.nl/). In BBMRI-NL,14
B180 biobanks from all over the Netherlands have been united,
including over 600 000 subjects with biological samples and phenotype
information. For 100 000 to 150 000 subjects genome-wide SNP data
are available, or are currently being generated. For the GoNL trio study,
four population-based biobanks provided samples:
1. LifeLines (http://lifelines.nl/lifelines-research/general), which is a
three-generation population-based cohort now including more
than 100 000 participants (target 160 000) representing B10% of
the northern part of the Netherlands.17
2. The Leiden Longevity Study (http://www.healthy-ageing.nl;
http://www.langleven.net), which includes 3500 persons from
families in which at least two long-lived siblings were alive and
their parents were of Caucasian descent.18
Figure 1 The 12 provinces of the Netherlands, the 12th province (Flevoland) is a recent province (land reclaimed from water) and was not included as a
separate sampling unit (Image by Wikimedia Commons user Alphathon).
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3. The Netherlands Twin Registry (NTR: http://www.tweelingenregister.
org), which ascertains two- and three-generation Dutch families
from the entire country based on the presence of twins or higher
order multiples in the family and includes nearly 180 000 partici-
pants.19,20 The NTR Biobank collected biological samples in
410000 participants.21
4. The Rotterdam studies, which consist of a population-based long-
term follow-up study including 11 800 persons from Rotterdam22
and its surrounding area (http://www.erasmus-epidemiology.nl/
rotterdamstudy) and the Genetic Research in Isolated Populations
program (GRIP: http://www.epib.nl/research/geneticepi/research.
html#gip) targeting the south western part of the Province
North-Brabant.
Table 1 summarizes the geographical distribution of the GoNL
participants over the Netherlands. A total of 769 subjects were
included from 250 families. In 19 of the 250 families, 2 offspring
were sequenced, 11 monozygotic (MZ) and 8 dizyotic (DZ) twin pairs
(see Figure 2). All participants are part of active biobanks. For the
majority of participants information on their place of birth and place
of birth of their (grand) parents is known. As the participants come
from prospective studies, a wealth of phenotype data is available,
including risk factors for morbidity and mortality, and information
on lifestyle and medication use. As part of BBMRI-NL, these data will
be further enriched with metabolomics (NMR, mass spectrometry),
whole-genome epigenetic (450K Illumina methylation arrays) and
RNA-sequencing data. Information on morbidity is collected by
record linkage projects in the Netherlands with databases such as
PALGA (The nationwide network and registry of histo- and cyto-
pathology in the Netherlands), NKR (Netherlands Cancer
Registration) and others.
Table 2 provides the demographic background of the sample.
The mean maternal age at blood draw was 62 years (SD 8.4 years), the
mean paternal age 64 (SD 8.6 years) and that of the offspring 36 (SD
9.3 years). On average there is a 5 cm increase in height in the second
generation, as is consistent with general population data. Average BMI
values show the population to be relatively healthy, although persons
with severe obesity are also observed. Lipid levels are relatively low, in
line with the low BMI and the relatively high percentage of lipid
lowering medication users in the Dutch population.
Sequencing
A coverage of 12x in both parents and the offspring was chosen based
on balancing sensitivity (calling completeness) and accuracy (erro-
neous false-positive variants), within budgetary limits.23 This design
gives 500 haplotypes at reasonable depth (that is, those transmitted to
the children) and 500 haplotypes at half of that depth (that is, those
not transmitted to the children). This design should significantly
contribute to the globally existing information, as, for example, the
1000 Genomes Project has a 4x coverage. Paired-end sequencing of
genomic DNA was done on the Illumina HiSeq 2000 platform
(Illumina Inc., San Diego, CA, USA) at the Beijing Genomics
Institute (BGI), starting in October 2010 and finished in June of
2011. Additionally, for each sample micro-array SNP data
(Immunochip on all samples and at least one other GWAS array
per sample) were generated by the biobanks. Sequencing was
performed on 2–3 DNA libraries per sample which were run on 2–
4 lanes of HiSeq 2000. The raw reads were subsequently analyzed
following 1000 Genomes best practices, in collaboration with the
Broad Institute and BGI. When reads were aligned against build 37 of
the human genome coverage was, as expected, randomly Poisson
distributed over the genome with a coverage peak in between 14–15x.
The reads were cleaned by indel realignment, duplicate read marking
and quality score recalibration, and SNP variants were called with a
trio-aware caller. In parallel, a wide variety of short indels and
complex structural variants were called and the SNPs were phased for
imputation. Data processing involved 200 000 h of computation and
was run on the Dutch national Target and BigGrid compute facilities
Next Gen Sequencing
~ 12x coverage
Illumina HiSeq 2000 platform
Genotyping
Minimal 2 array platforms / sample
ImmunoChip + others  
BioBank
Amsterdam
BioBank
Groningen BioBank
Rotterdam
BioBank
Leiden
One
Child
769
Dizygotic
Twins8 x
Monozygotic
Twins11 x
231 x
+
Individuals
Figure 2 Sampling schedule for the GoNL: four population-based biobanks contributed samples for sequencing at the BGI (Beijing Genomics Institute).
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supported by CIT/Groningen and SARA/Amsterdam. This effort
resulted in 60 TB of aligned reads and variant calls (http://
www.rug.nl/target/infrastructuur, http://www.biggrid.nl/). While
the sequencing technology and data processing pipelines are being
improved continually, variant detection, including short indels and
complex structural variants in low-complexity regions continue to
pose a challenge. The GoNL data analysis group applied Genome
Analysis Toolkit (GATK) BreakDancer, Pindel,24 GenomeSTRiP,
CNVnator, 123SV and DWAC-seq to discover and genotype diverse
types of variants such as SNPs, insertions, deletions, tandem
duplications, inversions and translocations.25 Each of these tools
showed its own variation detection characteristics, and the joint
use of the tools turned out most powerful. Detailed analytical
descriptions of SNP and SV calling, and de novo and loss-of-
function variants will be reported separately. Detection of de novo
mutations and accurate genotyping from pedigree data is
challenging, especially at low or intermediate depth of coverage.
Both require accurate and quantitative calibration of the evidence
supporting the individuals’ genotypes using all the available
information, including their familial relationship and population
allele frequency.
Genomic structure of the Netherlands
To describe the regional genomic differences in the genetic make-up
across the Netherlands, principal component analysis (PCA) was run
using the EIGENSOFT package.26 The PCA was first run on 4441
unrelated Dutch individuals15 typed on the Affymetrix Human
Genome-Wide SNP 6.0 Array (Affymetrix Inc., Santa Clara, CA,
USA), with a SNP set excluding 24 long-range LD regions27 and LD-
based SNP pruning (based on a variance inflation factor of 2),
resulting in a set of 130 248 SNPs. These PCs were then projected on
the 769 GoNL samples (using SNP calls release 2). Figure 3
summarizes the PC 1 versus PC 2 and the PC 1 versus PC 3 plots.
Three PCs correlated significantly with geographic location and
distinguished between: (1) the North and South of the Netherlands;
(2) between the East and West; and (3) between the middle-band of
the Netherlands and the rest of the country. When projected on the
GoNL individuals, for whom we have the province of the current
Table 2 Demographic characteristics and basic phenotypes for the GoNL participants. Values in brackets indicate ranges
Birth year
Average
age at
sampling
(year)
Average
height
(cm)
Average
BMI (kg/m2)
Average
TC level
(mmol/l)
Average
HDL level
(mmol/l)
Average
LDL level
(mmol/l)
Average
TG level
(mmol/l)
Fathers (N¼250) 1910–64 63.8 (46–87) 178 (160–198) 26.8 (18.1–39.6) 5.42 (2.98–8.23) 1.24 (0.60–2.30) 3.48 (1.29–5.70) 1.56 (0.10–4.80)
Mothers (N¼250) 1910–64 61.7 (43–86) 166 (145–182) 27.0 (18.6–38.9) 5.67 (3.10–8.70) 1.51 (0.55–2.46) 3.54 (1.48–6.40) 1.35 (0.16–4.65)
Sons (N¼105) 1945–89 36.1 (20–59) 183 (167–200) 25.1 (17.8–36.6) 4.86 (2.59–7.20) 1.17 (0.61–1.82) 3.07 (0.83–5.35) 1.44 (0.32–4.58)
Daughters (N¼163) 1940–94 35.9 (19–58) 171 (156–185) 24.6 (18.1–41.6) 4.74 (2.20–7.61) 1.48 (0.61–2.48) 2.79 (0.70–5.40) 1.09 (0.24–4.50)
−
0.0
2
−
0.0
1
0.0
0
0.0
1
0.0
2
0.0
3
0.0
4
−0.04
−0.02
0.00
0.02
0.04
PC 2
PC
 1
North−Holland
South−Holland
Zeeland
Utrecht
North−Brabant
Limburg
Gelderland
Overijssel
Flevoland
Friesland
Drenthe
Groningen
−
0.03
−
0.02
−
0.01 0.00 0.01 0.02 0.03
−0.04
−0.02
0.00
0.02
0.04
PC 3
PC
 1
Figure 3 PCA results highlighting differences in genetic make-up across the Netherlands: the plots give PC1 versus PC2, and PC1 versus PC3.
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living address available, it is clear from Figure 3, that PCs capture the
geographical variation in the data very well.
CONCLUSION
The goal of GoNL is to establish a reference set of variants in the
Dutch human genome that have a frequency of at least 0.5% by
whole-genome sequencing of 1000 independent genomes. Our pilot
analyses reveal that new variants are likely to emerge compared with
1000 Genomes and may thus contribute to sequence data acquired by
others. The GoNL project includes a number of unique aspects
compared with other ongoing projects (see Table 3). The sequencing
of GoNL was based on DNA isolated from blood (untransformed
cells), whereas sequencing in 1000 Genomes involved DNA derived
from transformed lymphoblastoid cell lines. Second, the embedding
of the study in population-based prospective epidemiological cohorts
enables research of clinical outcomes associated with mutations.
Third, the trio design of the project in combination with the medium
coverage of each genome allows estimation of haplotypes accurately,
and to call a substantial amount of the more rare and de novo
variation (both SNPs and structural variants). For 19 families,
additional monzygotic or dizygotic twin siblings were sequenced,
which allows in-depth research targeting new variants. Finally, the
additional data on clinical phenotypes, epigenetics, RNA sequencing
and the metabolome of the sequenced individuals will allow func-
tional studies of new variants.
One of the main purposes is to catalog both common and rare
variants, and to use the Dutch reference genome as a basis to
computationally infer the corresponding information in a much
larger data set of 100–150 thousand Dutch GWAS samples that have
been generated in the Dutch population. The creation of an
imputation pipeline is an important deliverable of GoNL. An
imputation pipeline was created on the European Grid network for
cohorts participating in BBMRI-NL, which can also be used by
cohorts from elsewhere. The pipeline requires cohorts to upload their
imputation-ready genotype data. Next, the process aligns the data
with the Dutch and/or combined reference set and imputation will be
done following recent protocols like the ones for the GIANT (the
Genetic Investigation of ANthropometric Traits) consortium, using
parallel grid computing. Afterwards, the full results including para-
meters for imputation quality can be downloaded by the cohort. The
quality of imputation depends on several features of the input data
and on the quality of the haplotype structure in the reference genome.
The trio design with medium sequence coverage enables us to
establish an accurately haplotyped Dutch reference genome, as the
presence of Mendelian transmissions of variants provided an extra
level of quality control and aided in the correct estimation of both
genotypes and haplotypes.
The GoNL trio design allows calling a substantial amount of
de novo variation (both SNPs and structural variants). It was recently
shown that there is considerable variation in mutation rates within
and between families, which in part can be attributed to the age of the
father at the time of conception.28 With a cohort of 250 families, we
will be able to further our understanding of mutational processes, in
particular as GoNL also includes 19 families with two twin offspring.
The twin pairs will allow us to address questions related to the
developmental timing of de novo mutations and the frequency of
germline mosaicism.
The GoNL data can also be used to address questions related to the
demographic history of the Dutch as in-depth information on both
mitochondrial29 DNA and Y-chromosome will become available.
Of immediate utility to the Dutch scientific community is the use
of GoNL as a reference for clinical and medical-sequencing projects.
Several founder mutations have previously been identified among the
Dutch16 including founder mutations in the BRCA1/2 (hereditary
breast cancer), LDLR (dyslipidemia) and Tau (dementia) genes. These
findings predict that many genes may incorporate region and
population-specific variants. The geographical variation observed in
our preliminary analyses of substructure corroborates the importance
of the original selection of GoNL samples dispersed throughout the
Netherlands. The Dutch samples thus far included in multi-center
GWAS studies originate from several different places in the
Netherlands and may thus optimally benefit from imputation when
the reference material properly reflects this provenance.
Within BBMRI-NL, several additional projects aim at harmoniza-
tion and enrichment of biobanks within the Netherlands at a national
scale. These projects include epigenetic studies, RNA sequencing and
metabolomics projects.14 To fully understand the functional
consequences of genetic variation, we have to integrate across
these levels of information. The Dutch biobanks also contain a
wealth of phenotypic information, which will become instrumental in
pinpointing genes and genetic variants in disease. GoNL will be an
excellent starting point to enrich the GWAS samples with more
functional DNA variation, and with the BBMRI-NL infrastructure
there is an excellent basis to further explain the functional
consequences of disease-associated variants.
Data access
GoNL aims to be an open research source for researchers in the
Netherlands and the rest of the world. The sequence data will be made
available through dbGaP (http://www.ncbi.nlm.nih.gov/gap).
Requests for data can be addressed to the steering committee of
GoNL (see http://www.nlgenome.nl).
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